MAPT and Alzheimer disease: Examples in this regard are the compounds [18F]-MK-6240, [18F]-PI-2620, [18F]-RO-948, and [18F]-APN-1607, which showed good performances in discriminating AD from non-AD patients in in vivo PET imaging studies [131,132,133,134], and also helping to detect low levels of Tau.